


*Serum Nitrate, a nitric oxide
generation product as a new
prognostic marker in liver cirrhosis*

Thesis

Submitted for partial fulfillment of Master Degree in
Clinical and Chemical Pathology



By

Esraa M. Fathi El-Shahat
M.B.B.Ch.

Laila M. Abc El M...

Under Supervision of

Prof.Dr. Sawsan Hosni Hamza

*Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain-Shams University*

55776

Ass.Prof.Dr. Nashwa Adel El-Badawi

*Assistant Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain-Shams University*

Nashwa El Badawi


Dr. Arig Ali Seif

*Lecturer of Clinical and Chemical Pathology
Faculty of Medicine, Ain-Shams University*

Arig Ali Seif

**Faculty Of Medicine
Ain-Shams University
1997**





*To My Dear Parents For Their
Continuous Support And Their
Encouragement Throughout My Life.
And To My Husband For His
Encouragement, Considerations and
Endless Patience.*



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿... وَمَا أُوتِيتُمْ مِّنَ الْعِلْمِ إِلَّا قَلِيلًا﴾

صدق الله العظيم

سورة الإسراء ... من الآية ٨٥

ACKNOWLEDGEMENT

First and foremost, thanks to God.

*I wish to express my sincere gratitude and appreciation to **Prof. Dr. Sawsan Hosni Hamza**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for giving me the privilege of working under her supervision, eminent guidance, continuous encouragement and valuable criticism and instructions. No words can express my respect to her thoughtfulness and overwhelming kindness.*

*My deepest thanks and most sincere gratitude go to **Ass. Prof. Dr. Nashwa Adel El-Badawi**, Assistant Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her close supervision, generous guidance, enlightening suggestions and creative ideas. I must admit that I consider myself very fortunate and I am proud to have worked under her supervision.*

*I am deeply indebted to **Dr. Arig Ali Seif**, Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her valuable corrections, worthy criticism and great cooperation throughout the whole work. I would like to take this opportunity to thank her for everything she has done for me.*

Finally, I would like to deeply thank all my colleagues at the department of Clinical Pathology, Faculty of Medicine, Ain Shams University, for their encouragement and support.

List of Contents

<i>List of Abbreviations.</i>	<i>Page</i> <i>i</i>
<i>List of Tables.</i>	<i>ii</i>
<i>List of Figures.</i>	<i>iii</i>
<i>Introduction and Aim of the Work.</i>	<i>1</i>
<i>Review of Literature</i>	
I-Nitric Oxide	4
<i>A-Biosynthesis and release of NO.</i>	<i>4</i>
<i>B-Actions of NO.</i>	<i>8</i>
<i>C-Physiological roles of NO.</i>	<i>12</i>
<i>D-Role of NO as a free radical.</i>	<i>18</i>
<i>E-NO in pathological diseases.</i>	<i>20</i>
II-Liver Cirrhosis	
<i>Definition</i>	<i>26</i>
<i>Classification</i>	<i>26</i>
<i>Major sequelae of cirrhosis</i>	<i>31</i>
<i>1-Portal hypertension</i>	<i>31</i>
<i>2-Ascites.</i>	<i>32</i>
<i>3-HRS.</i>	<i>34</i>
<i>4-Hepatic encephalopathy.</i>	<i>37</i>
III-The role of NO in the hyperdynamic circulatory syndrome associated with portal hypertension.	40
IV-Methods for determination of NO and its metabolites.	45
<i>Subjects and Methods</i>	<i>51</i>
<i>Results and Discussion</i>	<i>73</i>
<i>Summary and Conclusion</i>	<i>108</i>
<i>Recommendations</i>	<i>110</i>
<i>References</i>	<i>111</i>
<i>Appendix</i>	<i>I</i>
<i>Arabic Summary</i>	


List of Abbreviations

ALP:	Alkaline phosphatase.
ALT:	Alanine transaminase.
ADP:	Adenosine diphosphate.
AIDS:	Adults immunodeficiency syndrome.
ATP:	Adenosine triphosphate.
AST:	Aspartate transaminase.
BCP:	Bromocresol purple.
BUN:	Blood urea nitrogen.
Ca ²⁺ :	Calcium.
DW:	Distilled water.
cGMP	Cyclic guanosine monophosphate.
EDRF:	Endothelial-derived relaxing factor.
FAD:	Flavin adenine dinucleotide.
FN:	False negative.
FP:	False positive.
γ-INF	γ-interferon.
GGT:	γ-glutamyl transpeptidase.
hANP:	Human atrial natriuretic peptide.
H ₃ PO ₄	Phosphoric acid.
HRS:	Hepatorenal syndrome.
IL-1:	Interleukin-1.
KOH:	Potassium hydroxide.
β-NADP:	β-nicotinamide adenine dinucleotide phosphate.
β-NADPH:	β-nicotinamide adenine dinucleotide phosphate (reduced form).
NO:	Nitric oxide.
NOS:	Nitric oxide synthase.
PPB	Part per billion.
RB:	Reagent blank.
S:	Sample.
SB:	Sample blank.
TN:	True negative.
TNF:	Tumor necrosis factor.
TP:	True positive.

	<i>Page</i>
Table 1: Causes of liver cirrhosis	27
Table 2: Major sequelae of cirrhosis	30
Table 3: Clinical characteristics of the studied groups of patients.	53
Table 4: Laboratory results of control and patients groups	74
Table 5: Comparative statistical studies between control group and all patient groups using "t" test..	75
Table 6: Comparative statistical studies between control group and group I using "t" test.	75
Table 7: Comparative statistical studies between control group and group II using "t" test.	76
Table 8: Comparative statistical studies between group IIa and group IIb using "t" test.	76
Table 9: Comparative statistical studies between control group and group III using "t" test.	77
Table 10: Comparative statistical studies between group I and group II using "t" test.	78
Table 11: Descriptive statistical data of serum nitrate.	92
Table 12: Statistical comparison between different studied groups regarding serum nitrate using "t" test.	92
Table 13: Correlation study between studied laboratory results and serum nitrate among all patient groups.	94
Table 14: Correlation study between studied laboratory results and serum nitrate among group I.	95
Table 15: Correlation study between studied laboratory results and serum nitrate among group II.	95
Table 16: Correlation study between studied laboratory results and serum nitrate among group III.	96
Table 17: ANOVA between all studied patient groups.	102
Table 18: Kruskal Wallis test.	103
Table 19: Diagnostic reliability for S.nitrate for differentiating cirrhotic patients.	104
Table 20: Diagnostic reliability for S.nitrate for differentiating patients with HRS.	104

List of Figures

<i>List of Figures</i>		<i>Page</i>
Figure 1:	Biosynthesis of NO from L-arginine.	6
Figure 2:	Two types of NO synthesis in endothelium and macrophage.	7
Figure 3:	Action of NO on smooth muscle.	9
Figure 4:	The dynamic activity of blood in vascular.	11
Figure 5:	The hypothetical role of control NO in portal hypertension.	43
Figure 6:	Pie chart for all studied groups.	54
Figure 7:	Scatter diagram of serum nitrate in all studied groups.	79
Figure 8:	Comparative study of serum nitrate in different studied groups.	80
Figure 9:	Comparative study of total bilirubin in different studied groups.	81
Figure 10:	Comparative study of direct bilirubin in different studied groups.	82
Figure 11:	Comparative study of total protein in different studied groups.	83
Figure 12:	Comparative study of albumin in different studied groups.	84
Figure 13:	Comparative study of AST in different studied groups.	85
Figure 14:	Comparative study of ALT in different studied groups.	86
Figure 15:	Comparative study of albumin in different studied groups.	87
Figure 16:	Comparative study of GGT in different studied groups.	88
Figure 17:	Comparative study of BUN in different studied groups.	89
Figure 18:	Comparative study of creatinine in different studied groups.	90
Figure 19:	Correlation study between serum nitrate and albumin among group I.	97
Figure 20:	Correlation study between serum nitrate and albumin among all patients group.	98
Figure 21:	Correlation study between serum nitrate and BUN among all patient group.	99
Figure 22:	Correlation study between serum nitrate and creatinine among all patient group.	100
Figure 23:	ROC curve to determine the optimal serum nitrate level for diagnosis of cirrhosis.	105
Figure 24:	ROC curve to determine the optimal serum nitrate level for diagnosis of HRS.	106



Introduction and Aim of the Work

In 1980, *Furchgott and Zawadzki* demonstrated that an endothelium-derived relaxing factor was responsible for acetyl choline dependent vasodilatation. This factor was later shown to be nitric oxide (NO), a molecule which is implicated in certain pathophysiological processes such as control of blood vessel tone, neurotransmission, host immune defense, septic shock and atherosclerosis (*Mancada and Higgs, 1993; and Lowenstein et al., 1994*).

Nitric oxide is synthesized by the enzyme nitric oxide synthetase from the amino acid L-arginine and diffuses toward the target cells, for example, NO synthesized in endothelial cells diffuses through the smooth muscle cells and is responsible for relaxation by activating the soluble guanylate cyclase (*Palmer et al., 1988*).

Nitric oxide is important for cellular signaling in non-hepatic tissues, and recent evidence suggests that it may be important regulatory of some liver functions. The liver can produce considerable amounts of NO under both constitutive and inducible conditions and may play a critical role in the arteriolar vasodilatation, high cardiac output and systemic hyperdynamic state of cirrhosis (*Vallance and Mancada, 1991*).

Nitric oxide is an extremely lipid soluble gas and undergoes rapid oxidative degradation to the stable breakdown products, nitrates and nitrites. Upon entering the vascular system, nitrite react rapidly with

Introduction and Aim of the Work

oxyhaemoglobin resulting in the formation of methaemoglobin, while nitrates remain stable in the circulation, therefore NO is best determined in the serum as nitrates (*Bories and Bories, 1995*).

Increased concentrations of NO breakdown products have been described in patients with sepsis syndrome, in advanced cancer patients receiving interleukin-2 therapy, rheumatoid arthritis, epilepsy, hypoxic ischemic cerebral injury (*Hibbs et al., 1992; and Evans et al., 1993*).

It has been documented that cirrhotic patients have a significant increase in the concentrations of serum nitrate and nitrite compared with control groups (*Guarner et al., 1993; and Albillos et al., 1995*) and consequently, as cirrhosis progresses, vascular resistance continue to fall. Such vasodilatation produced by high NO level may persist, the resulting hypotension may lead to secondary disturbances in renal, hepatic blood flow, and ascites. Indeed, the degree of haemodynamic disturbance correlates with prognosis (*Bosch et al., 1988; and Knowles et al., 1990*).

Aim of the Work

In this study, measurement of serum nitrate, as an index of nitric oxide generation is done in a trial to establish a relation ship between nitric oxide level and the clinical progression of liver cirrhosis. Moreover, the role of serum nitrate in providing prognostic information to identify those patients at risk of developing hepatorenal syndrome will be highlighted for treatment modulating purposes.